Regulation Tracker
FDA warning letter tracker
80+ companies in this category have received FDA warning letters since 2025 — overwhelmingly about marketing claims, not product safety. Here's the timeline, and how to tell the difference.
Why this page exists
An FDA warning letter is the clearest public signal that a company's conduct has drawn regulatory
attention. It is not always a product-safety finding — most letters in this category concern
marketing claims. But the distinction is one most review sites never make, so people
either panic or ignore it entirely.The enforcement timeline
| Date | Action | Who it hit |
|---|---|---|
| Sept 2025 | 50–55+ warning letters over misleading direct-to-consumer advertising | GLP-1 compounders and manufacturers, US and international |
| Feb 4–6, 2026 | FDA announces intent to restrict GLP-1 active ingredients in mass-marketed non-approved compounded products; threatens seizure and injunction | The compounded GLP-1 market broadly |
| Feb 9, 2026 | Novo Nordisk sues Hims & Hers for patent infringement | Hims & Hers |
| Feb 20, 2026 (public Mar 3) | 30 further warning letters for false or misleading claims | 30 telehealth companies marketing compounded GLP-1s |
| 2026 (ongoing) | Letters targeting peptides sold as ‘research use only’ where marketing implied human use | Sellers of semaglutide, tirzepatide, retatrutide, BPC-157, SARMs |
How to read a warning letter
| If the letter concerns... | How worried to be |
|---|---|
| Marketing claims (equivalence to brand, ‘proven results’) | A compliance flag. Real, but not a finding about what's in your vial. |
| Insanitary conditions at a compounder | Serious. This is a product-quality finding. Treat as disqualifying. |
| Unapproved product / illegal marketing to consumers | Structural risk — the business model may not survive enforcement. |
Where our reviewed providers stand
| Provider | Status |
|---|---|
| MEDVi | Received a Feb 2026 FDA warning letter — marketing claims, not product quality. Disclosed in our review. |
| Peter MD | No warning letter to the platform; its named pharmacy partners carry documented warning-letter history. |
| Henry Meds | No FDA warning letter on record for Henry Meds or parent Adonis Health. Separately, Eli Lilly has sued over its oral tirzepatide. |
| Hone Health | No FDA warning letter on record. |
| Marek Health | No FDA warning letter on record. |
| TrimRx / Willow / FormBlends | No FDA warning letter on record at time of verification. |
A warning letter is not automatically disqualifying
Roughly 80+ companies in this category received letters across 2025–2026, overwhelmingly for
marketing language. If we disqualified every provider that got one, we'd have very little to review. What
we do instead is disclose it, weight it into the pharmacy-sourcing and compliance scoring, and tell you
what the letter was actually about.This tracker updates
We re-verify against the FDA warning-letter database and update as new letters issue. Verified
July 2026.FAQ
Which peptide providers have FDA warning letters?
Across 2025–2026 the FDA issued 80+ letters to GLP-1 compounders and telehealth marketers, the majority concerning misleading direct-to-consumer advertising rather than product quality. Of the providers we review, MEDVi received a February 2026 letter over marketing claims. We disclose it in their review.
Does a warning letter mean the medication is unsafe?
Usually not. Most letters in this category address marketing claims — implying equivalence to FDA-approved drugs, or claiming proven results. A letter about insanitary conditions at a compounding facility is a different and far more serious matter.
Should I avoid a provider with a warning letter?
Not automatically — that would eliminate most of the category. Read what the letter was about. A marketing-claims letter is a compliance flag; an insanitary-conditions finding at the compounding pharmacy is disqualifying.
Medical disclaimer: Veritide is an independent consumer-research publication, not a healthcare provider or pharmacy. This page is informational and is not medical advice. Compounded medications are not FDA-approved as finished products. Always consult a licensed clinician before starting any peptide or GLP-1 therapy.